Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy - PubMed (original) (raw)
Comparative Study
. 2005 Aug 2;46(3):470-6.
doi: 10.1016/j.jacc.2005.02.090.
Barry J Maron, Iacopo Olivotto, Martin S Maron, Franco Cecchi, Sandro Betocchi, Bernard J Gersh, Michael J Ackerman, Robert B McCully, Joseph A Dearani, Hartzell V Schaff, Gordon K Danielson, A Jamil Tajik, Rick A Nishimura
Affiliations
- PMID: 16053960
- DOI: 10.1016/j.jacc.2005.02.090
Free article
Comparative Study
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy
Steve R Ommen et al. J Am Coll Cardiol. 2005.
Free article
Abstract
Objectives: This study sought to determine the impact of surgical myectomy on long-term survival in hypertrophic cardiomyopathy (HCM).
Background: Left ventricular (LV) outflow tract obstruction in HCM increases the likelihood of heart failure and cardiovascular death. Although surgical myectomy is the primary treatment for amelioration of outflow obstruction and advanced drug-refractory heart failure symptoms, its impact on long-term survival remains unresolved.
Methods: Total and HCM-related mortality were compared in three subgroups comprised of 1,337 consecutive HCM patients evaluated from 1983 to 2001: 1) surgical myectomy (n = 289); 2) LV outflow obstruction without operation (n = 228); and 3) nonobstructive (n = 820). Mean follow-up duration was 6 +/- 6 years.
Results: Including two operative deaths (procedural mortality, 0.8%), 1-, 5-, and 10-year overall survival after myectomy was 98%, 96%, and 83%, respectively, and did not differ from that of the general U.S. population matched for age and gender (p = 0.2) nor from patients with nonobstructive HCM (p = 0.8). Compared to nonoperated obstructive HCM patients, myectomy patients experienced superior survival free from all-cause mortality (98%, 96%, and 83% vs. 90%, 79%, and 61%, respectively; p < 0.001), HCM-related mortality (99%, 98%, and 95% vs. 94%, 89%, and 73%, respectively; p < 0.001), and sudden cardiac death (100%, 99%, and 99% vs. 97%, 93%, and 89%, respectively; p = 0.003). Multivariate analysis showed myectomy to have a strong, independent association with survival (hazard ratio 0.43; p < 0.001).
Conclusions: Surgical myectomy performed to relieve outflow obstruction and severe symptoms in HCM was associated with long-term survival equivalent to that of the general population, and superior to obstructive HCM without operation. In this retrospective study, septal myectomy seems to reduce mortality risk in severely symptomatic patients with obstructive HCM.
Comment in
- The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy.
Watkins H, McKenna WJ. Watkins H, et al. J Am Coll Cardiol. 2005 Aug 2;46(3):477-9. doi: 10.1016/j.jacc.2005.05.013. J Am Coll Cardiol. 2005. PMID: 16053961 No abstract available.
Similar articles
- Does myectomy convey survival benefit in hypertrophic cardiomyopathy?
Woo A, Rakowski H. Woo A, et al. Heart Fail Clin. 2007 Jul;3(3):275-88. doi: 10.1016/j.hfc.2007.04.010. Heart Fail Clin. 2007. PMID: 17723936 Review. - The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy.
Watkins H, McKenna WJ. Watkins H, et al. J Am Coll Cardiol. 2005 Aug 2;46(3):477-9. doi: 10.1016/j.jacc.2005.05.013. J Am Coll Cardiol. 2005. PMID: 16053961 No abstract available. - Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy.
Smedira NG, Lytle BW, Lever HM, Rajeswaran J, Krishnaswamy G, Kaple RK, Dolney DO, Blackstone EH. Smedira NG, et al. Ann Thorac Surg. 2008 Jan;85(1):127-33. doi: 10.1016/j.athoracsur.2007.07.063. Ann Thorac Surg. 2008. PMID: 18154797 - Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy.
Ferrazzi P, Spirito P, Iacovoni A, Calabrese A, Migliorati K, Simon C, Pentiricci S, Poggio D, Grillo M, Amigoni P, Iascone M, Mortara A, Maron BJ, Senni M, Bruzzi P. Ferrazzi P, et al. J Am Coll Cardiol. 2015 Oct 13;66(15):1687-96. doi: 10.1016/j.jacc.2015.07.069. J Am Coll Cardiol. 2015. PMID: 26449139 - Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients.
Maron BJ, Yacoub M, Dearani JA. Maron BJ, et al. Eur Heart J. 2011 May;32(9):1055-8. doi: 10.1093/eurheartj/ehr006. Epub 2011 Feb 14. Eur Heart J. 2011. PMID: 21324934 Review.
Cited by
- Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial.
Desai MY, Okushi Y, Gaballa A, Wang Q, Geske JB, Owens AT, Saberi S, Wang A, Cremer PC, Sherrid M, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Lampl KL, Sehnert AJ, Nissen SE, Popovic ZB; VALOR-HCM Investigators. Desai MY, et al. Circ Cardiovasc Imaging. 2024 Sep;17(9):e017185. doi: 10.1161/CIRCIMAGING.124.017185. Epub 2024 Sep 2. Circ Cardiovasc Imaging. 2024. PMID: 39221824 Free PMC article. Clinical Trial. - Modern Perspectives on Hypertrophic Cardiomyopathy-No One Size Fits All.
Doliner B, Gaddar H, Kalil R, Postalian A. Doliner B, et al. Tex Heart Inst J. 2024 Aug 1;51(2):e248423. doi: 10.14503/THIJ-24-8423. Tex Heart Inst J. 2024. PMID: 39086311 Free PMC article. Review. - Myocardial contractility characteristics of hypertrophic cardiomyopathy patients with and without sarcomere mutation.
Zhang J, Li J, Wang B, Wang J, Hu R, Shan B, Han Y, Zhao X, Zhang J, Zhang Y, Ta S, Liu L. Zhang J, et al. Heart Vessels. 2024 May 28. doi: 10.1007/s00380-024-02414-5. Online ahead of print. Heart Vessels. 2024. PMID: 38806839 - Evolving Strategies for the Management of Obstructive Hypertrophic Cardiomyopathy.
Liang LW, Lumish HS, Sewanan LR, Shimada YJ, Maurer MS, Weiner SD, Clerkin KJ. Liang LW, et al. J Card Fail. 2024 Sep;30(9):1136-1153. doi: 10.1016/j.cardfail.2024.04.024. Epub 2024 May 20. J Card Fail. 2024. PMID: 38777216 Review. - Comparing long-term outcomes of septal myectomy and mitral valve replacement in hypertrophic cardiomyopathy patients: A retrospective cohort study in Iran.
Ayati A, Khoshfetrat M, Davoodi S, Ahmadi Tafti SH, Arefizadeh R. Ayati A, et al. Health Sci Rep. 2024 Apr 15;7(4):e2045. doi: 10.1002/hsr2.2045. eCollection 2024 Apr. Health Sci Rep. 2024. PMID: 38629112 Free PMC article.